Priyanka Gupta currently serves as an Associate Research Fellow and Director at Pfizer, where she leverages her extensive expertise in preclinical pharmacology to drive innovative drug discovery initiatives. With a robust background in pharmacokinetics (PK) and pharmacodynamics (PD), Priyanka has dedicated over eight years to...
Priyanka Gupta currently serves as an Associate Research Fellow and Director at Pfizer, where she leverages her extensive expertise in preclinical pharmacology to drive innovative drug discovery initiatives. With a robust background in pharmacokinetics (PK) and pharmacodynamics (PD), Priyanka has dedicated over eight years to the advancement of biologics, particularly monoclonal antibodies and antibody-drug conjugates (ADCs). Her work spans multiple therapeutic areas, including oncology, neurology, and infectious diseases, where she applies her deep understanding of PK/PD principles to optimize drug development processes.
Since the integration of Seagen Inc. into Pfizer, Priyanka has been at the forefront of several key projects aimed at enhancing the efficacy and safety profiles of novel therapeutics. Her role involves not only the design and execution of preclinical studies but also the application of advanced modeling and simulation techniques to predict clinical outcomes. This strategic approach has proven invaluable in guiding decision-making throughout the drug development lifecycle, ensuring that promising candidates progress efficiently through clinical trials.
Priyanka’s strong skill set encompasses various aspects of drug development, biotechnology, and assay development, making her a vital contributor to Pfizer's mission of delivering transformative therapies to patients. Her commitment to scientific excellence and her ability to navigate the complexities of the pharmaceutical industry position her as a leader in the field, driving forward the next generation of biologic therapies that hold the potential to change lives.
